April 2010
Worldwide Biotech;Apr2010, Vol. 22 Issue 4, p7
Trade Publication
The article reports on the successful Good Manufacturing Practice audit of the manufacturing facility of Protalix BioTherapeutics Inc. in Carmiel, Israel, conducted by the Israeli Ministry of Health. The audit was part of the evaluation of Protalix BioTherapeutics' manufacturing process of taliglucerase alfa for the treatment of Gaucher disease. Data on the Phase III trial of taliglucerase alfa was presented by the firm at the World symposium of the Lysosomal Disease Network held in February 2010.


Related Articles

  • CRL for Gaucher's Drug; More Expenses Ahead for Protalix.  // Bioworld Week;3/7/2011, Vol. 19 Issue 10, p2 

    The article reports on the approval of the drug, a lead compound taliglucerase alfa for Gaucher's disease wherein the drugmaker Protalix BioTherapeutics Inc. has been working on the complete response letter (CRL) from the U.S. Food and Drug Administration. It was in November 2009 that Pfizer and...

  • Protalix Shrivels On Low-Ball Offering: $50M For Gaucher's. Osborne, Randall // BioWorld Today;10/26/2007, Vol. 18 Issue 209, p1 

    The article reports on a decline in the stock price of Protalix BioTherapeutics Inc. after the Israel-based company priced 10 million shares of its stock at only $5 per share. The shares of Protalix closed at $6.31, down $29.75, or 83 percent, on October 25, 2007 after the announcement of the...

  • FDA Gives Nod to Protalix's Elelyso in Gaucher Disease. Powers, Marie // BioWorld Today;5/3/2012, Vol. 23 Issue 86, p1 

    The article reports on the approval given by the U.S. Food and Drug Administration (FDA) to Elelyso, a recombinant version of the hydrolytic human lysosomal enzyme glucocerebrosidase, for Gaucher disease. The approval allows Elelyso to become the first plant cell-based enzyme replacement therapy...

  • PROTALIX TREATS FIRST GAUCHER PATIENT.  // Worldwide Biotech;May2013, Vol. 25 Issue 5, p1 

    The article reports on the pharmaceutical company Protalix BioTherapeutics Inc.'s first patient treatment on its orally-administered enzyme product candidate for Gaucher disease in the U.S. The company's PRX-112 is a plant cell form of glucocerebrosidase enzyme (GCD) which is encapsulated within...

  • Pfizer stakes a claim in plant cell–made biopharmaceuticals. Ratner, Mark // Nature Biotechnology;Feb2010, Vol. 28 Issue 2, p107 

    The article reports on the commitment of Pfizer to introduce a plant cell-based biologic drug to the market on December 1, 2009. The rights to taligurase alfa, a type of enzyme called glucocerebrosidase that is intended for the treatment of Gaucher's disease, were reportedly bought by Pfizer...

  • Genzyme Makes Gaucher Bids.  // Bioworld Week;11/9/2009, Vol. 17 Issue 45, p4 

    The article reports on the drug condition concentrating on Gaucher ERT Uplyso. This medicine has been directed to win the market in 2010 and will take on Genzyme Corp.'s market leader Cerezyme. Meanwhile, it mentions the Israeli newspaper "TheMarker" dealing with the possible collaboration of...

  • Protalix: $115M Gaucher's Deal Is Just the Beginning.  // Bioworld Week;12/7/2009, Vol. 17 Issue 49, p1 

    The article reports that Protalix Bio Therapeutics Inc. has unveiled a profit sharing deal with Pfizer Inc. for Gaucher's disease drug Uplyso. The deal resulted in the fall of around 13.7 percent in the value of shares of Protalix. According to Brian Abrahams, analyst at Oppenheimer & Co., the...

  • Protalix's Gaucher Drug May Fill Gap Left from Genzyme Plant Closure.  // BioPharm International;Aug2009, Vol. 22 Issue 8, p15 

    The article reports that the Food and Drug Administration (FDA) is asking Protalix BioTherapeutics to consider submitting a treatment protocol for the use of prGC, the company's development drug for patients with Gaucher disease. It states that the FDA believes the company's development program...

  • Protalix: $115M Gaucher's Deal with Pfizer is Just the Beginning. Morrison, Trista // BioWorld International;12/9/2009, Vol. 14 Issue 49, p5 

    The article reports on the 115-million U.S. dollar profit-sharing deal between Protalix BioTherapeutics Inc. and Pfizer Inc. for the development of Upsylo, a drug for Gaucher's disease. Milestone payments are expected to be given soon to the former as the drug application has a fast-track status...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics